What is the main business of TG Pharma?

The main business activity of TG Pharma focuses on other research and experimental development on natural sciences and engineering.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on September 2, 2020.

Where is the headquarters located?

The headquarters is located at: ul. Sienna 86, 00-815 Warszawa.

Who is on the management board?

The management board includes: Krzysztof Roman Grzyliński (President of the Management Board) and Witold Stanisław Tarkowski (Member of the Management Board).

What is the share capital?

The share capital of the company is PLN 500,000 (approx. $135,062).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2023 to December 31, 2023.

How much revenue was generated?

In 2023, the company generated total revenue of $0, representing an increase of 64.1% compared to 2022.

No, the company recorded a net loss of $39,395 in 2023. For comparison, in 2022 the loss was $46,500, meaning the company reduced its loss by 20.1%.

What is the main operating cost?

The largest operating cost category falls under external services. This category amounted to $37,180 in 2023, representing 98% of all operating expenses.

TG Pharmasp. z o.o.

Other research and experimental development on natural sciences and engineering

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2020-09-02

Share capital

500 000,00 PLN

Activity description

TG Pharma was founded in 2020 by physicians Krzysztof Grzyliński and Witold Tarkowski. The company is developing the medicinal product Demophta and planning non-clinical and clinical research into its use for chronic Demodex blepharitis.

Registered address

ul. Sienna 86/100, 00-815 Warszawa, Poland

Website

tgpharma.pl

Social media

Electronic delivery address

AE:PL-98263-96513-CCECS-23

Financials

Revenue history

Filing timeliness

No financial statement for 2024 – the filing deadline has passed. 3 of 3 financial statements were filed late (the longest delay 495 days for 2021).

2024not filed
202305/08/2024
202222/11/2023
202122/11/2023

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2023.

Results vs industry

Revenue

This companyUSD 0.25MedianUSD 73.59kAverageUSD 3.23m

Net profit

This companyUSD -39.40kMedianUSD 68.18AverageUSD 82.15k

Operating costs

This companyUSD 37.86kMedianUSD 76.09kAverageUSD 3.04m

Assets

This companyUSD 16.77kMedianUSD 120.07kAverageUSD 3.90m

Industry

Authorized Representatives

Mateusz Gołąb – Attorney-in-fact (sole)

Krzysztof Roman Grzyliński – President of the Management Board

Witold Stanisław Tarkowski – Management Board Member

Manner of representation

For making declarations of will concerning the rights and obligations of the company and for signing on behalf of the company, the President of the Management Board is authorized to act independently, or two members of the management board jointly.

Ownership

Owner	Shares	Share value	Stake
Mateusz Gołąbage 45	30	$40,518.64	30%
Portarina Ltd	20	$27,012.43	20%
Witold Stanisław Tarkowskiage 65	30	$40,518.64	30%
Others	20	$27,012.43	20%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2020-12-22.

Bank Pekao SA
73 1240 6292 1111 0011 0262 0013

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
Dec 16, 2024	De minimis aid (in accordance with Commission Regulation 2023/2831)	$867$867	Fundacja Koalicji na Rzecz Polskich Innowacji

Competitors

Name	Revenue	Website
Corab Technologysp. z o.o.	$1.43	corab.pl
ORCA ComputingBranch (foreign co.)	$0.32	orcacomputing.com
Iqcredosp. z o.o.	$0.20	iqcredo.com
Revobudsp. z o.o.	$0.17	revobuild.com
Divilinesp. z o.o.	$0.15	diviline.pl
Nanosono Medcaresp. z o.o.	$0.05	nanosonomedcare.eu